Dalbavancin

Description

1. Product Overview

Dalbavancin is a long-acting, semi-synthetic lipoglycopeptide antibiotic designed for the treatment of serious Gram-positive bacterial infections. It is primarily utilized in the pharmaceutical and healthcare industries, particularly for acute bacterial skin and skin structure infections (ABSSSI) caused by resistant pathogens such as Staphylococcus aureus. Its key value proposition lies in its extended half-life, enabling once-weekly dosing and significantly reducing hospitalization and administration costs. Strategically, Dalbavancin is critical in modern antimicrobial stewardship programs, offering an effective solution against resistant strains while improving patient compliance and healthcare efficiency.

2. Key Specifications & Technical Characteristics

• Chemical Composition: Semi-synthetic lipoglycopeptide derivative of glycopeptide antibiotics
• Molecular Formula: C₈₈H₁₀₀Cl₂N₁₀O₂₈
• Purity Level: ≥ 98% (pharmaceutical grade)
• Form: Sterile lyophilized powder
• Color: Off-white to pale yellow
• Solubility: Soluble in water for injection after reconstitution
• Packaging Options:
  • Sterile vials (500 mg, 1 g)
  • Bulk pharmaceutical-grade packaging for manufacturing use
• Shelf Life: 24–36 months under controlled storage conditions (2–8°C, protected from light)

3. Core Industrial Applications

Dalbavancin is widely used across the pharmaceutical manufacturing, hospital supply chains, and clinical treatment sectors. Its primary application is in the formulation of injectable antibiotics targeting multidrug-resistant Gram-positive infections, including MRSA.

Key operational use cases include:

• Production of long-acting injectable antibiotics for hospital and outpatient care
• Inclusion in antimicrobial stewardship protocols to reduce inpatient stays
• Use in decentralized healthcare systems where limited dosing frequency is critical

Compared to conventional antibiotics, Dalbavancin offers superior performance through:

• Extended dosing intervals, reducing administration frequency
• High efficacy against resistant strains, minimizing treatment failure rates
• Lower total treatment cost, due to reduced hospitalization and monitoring requirements

4. Competitive Advantages

• Quality Consistency: Manufactured under strict GMP-compliant processes ensuring batch-to-batch uniformity
• Supply Reliability: Scalable production capacity with robust global supply chain networks
• Logistics Capability: Cold-chain compliant packaging and international distribution support
• Price Competitiveness: Optimized production and bulk supply options for cost-efficient procurement
• Sustainability: Reduced healthcare resource utilization due to long-acting formulation
• Technical Support: Comprehensive documentation including COA, MSDS, and regulatory compliance dossiers available

5. Commercial & Supply Information

• Minimum Order Quantity (MOQ): Bulk 20 MT
• Loading Capacity:
  • Approx. 10–12 MT per 20-ft container
  • Approx. 20–25 MT per 40-ft container depending on packaging configuration